• Ann Tucker

FDA Issues Guidance to Expand Naloxone Access in Harm Reduction

Recently issued, new guidance from the FDA helps expand availability and access to naloxone for harm reduction programs. The guidance clarifies a public health emergency exclusion and exemption from requirements of the Drug Supply Chain Security Act (DSCSA) regarding the distribution of FDA-approved naloxone products to harm reduction programs and includes a related compliance policy. Although this guidance is immediately in effect, the FDA is accepting comments.

1 view0 comments

Recent Posts

See All

SAMHSA (11/10) –– The Substance Abuse and Mental Health Services Administration is pleased to announce the release of the agency’s Interim Strategic Plan (ISP), which presents a new mission and vision

The White House budget office is reviewing a draft SAMHSA rule that would make permanent the COVID-19 methadone take-home waiver and define which patients with OUD are considered “stable” enough to re